Neurogenic inflammation mediator

"Neurogenic inflammation mediators" is not a single molecule or receptor but rather a broad group of endogenous substances—primarily neuropeptides—released from sensory nerve endings that initiate and propagate inflammatory responses. Key examples include substance P, calcitonin gene-related peptide (CGRP), neurokinin A, and others. These mediators are released by afferent neurons in response to noxious stimuli via activation of ion channels such as TRPV1 and TRPA1. Once released, they act on local immune cells like mast cells to trigger the release of histamine and cytokines, creating a feedback loop that amplifies inflammation[1][4][7]. This process is implicated in various diseases with an inflammatory component—including migraine, asthma, psoriasis, fibromyalgia—and is distinct from classic immunologic inflammation because it originates from neural activity rather than immune cell activation alone[1][4]. Is there something wrong with this target? Yes. "Neurogenic inflammation mediators" refers to a class or group of molecules—not a specific molecular entity or druggable target such as an individual receptor or enzyme. Therefore: * It cannot be assigned a unique canonical name or abbreviation. * It does not correspond to one protein/gene/receptor but encompasses several different molecules. * There are no direct interacting drugs; instead, drugs may target individual members within this group (e.g., CGRP antagonists for migraine). * Mechanisms of action would depend on the specific mediator targeted. For structured data purposes in drug discovery databases or ontologies focused on molecular targets, this entry should be flagged as incorrect/unsuitable because it lacks specificity—it describes a functional category rather than an actionable molecular entity[1][3][4].

Other names

Neurogenic inflammatory mediatorneuropeptide mediator of neurogenic inflammationpro-inflammatory neuropeptide (context-dependent)